Abstract

Formestane (4-hydroxyandrostenedione) (Lentaron – Ciba) is the first of a new class of drugs that selectively inhibit aromatase, the enzyme that converts androgens to oestrogens. It is licensed for the treatment of postmenopausal women with advanced breast cancer and has been promoted by the manufacturer as offering new hope for those who have relapsed on tamoxifen.